Medicare on Tuesday issued its draft decision about Aduhelm, which comes with an annual price of $28,200 per patient. The Food and Drug Administration approved the drug in June even though its panel of scientific advisers said there was not enough evidence to show it was effective. |
No comments:
Post a Comment